Peptide-drug co-assembling: A potent armament against cancer

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Cancer remains a significant global health challenge with limited treatment efficacy.
• Peptide-based self-assembled delivery systems offer advantages like biocompatibility and ease of modification.
• Existing methods like physical encapsulation and covalent conjugation have drawbacks such as drug leakage and altered activity.

Purpose of the Study:

• To explore peptide-mediated co-assembly as an advanced strategy for cancer drug delivery.
• To review the design methodologies and applications of co-assembled nanostructures in cancer therapy.
• To discuss the advantages and challenges of co-assembly in the context of tumor treatment.

Main Methods:

• Classification of assembled peptides and analysis of co-assembly driving forces.
• Detailed examination of design strategies for incorporating various drug molecules into co-assembled nanostructures.
• Highlighting recent advancements in peptide-mediated co-assembled delivery systems for cancer treatment.

Main Results:

• Peptide-drug co-assembly enables the creation of versatile and stable nanostructures (nanotubes, nanofibrils, hydrogels, nanovesicles).
• This strategy overcomes issues associated with drug leakage and altered pharmacological activity seen in other methods.
• Co-assembled nanostructures demonstrate significant potential for enhanced tumor therapy.

Conclusions:

• Peptide-mediated co-assembly represents a promising platform for developing next-generation cancer therapeutics.
• Further research is needed to address existing challenges and fully realize the potential of co-assembly in clinical applications.
• Co-assembly offers improved versatility and stability for drug delivery compared to conventional approaches.